StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

361 Study Matches

First Carpometacarpal Osteoarthritis Evaluation: Determining the Concurrent Validity and Test-Retest Reliability of the Thumb Disability Index (TDX) and Test-retest Reliability of Thumb Position Sense-Error using the Intermetacarpal Distance (IMD) Method

We are studying different questionnaires used to measure symptoms and activity limitations that are linked to thumb arthritis. We are also studying ways to measure thumb position sense in persons with thumb arthritis.

Corey McGee, PhD, MS, OTR/L, CHT
18 years and over
This study is NOT accepting healthy volunteers
STUDY00006741
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• osteoarthritis of the joint where the bones of the wrist meet the hand (CMC)
Exclusion Criteria:

• received steroid injection treatment in the past 3 months
• history of CMC joint replacement
• nerve problems in the wrist or hand
• women who are pregnant
• unable to speak English
Arthritis & Rheumatic Diseases
Arthritis, CMC, CMC/Carpometacarpal, Osteoarthritis
I'm interested
Share via email

Udall P1A4

Through this research, the study staff hopes to better understand how DBS works and to define the optimal site in the brain for DBS treatment for Parkinson’s Disease. You will be asked to come for one study visit where you will perform some physical and mental tasks while on and temporarily off your medications and DBS treatment. Participation in this research study will take 7-8 hours.

Jerrold Vitek
Not specified
This study is NOT accepting healthy volunteers
STUDY00019735
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 10 years old
• diagnosis or suspected diagnosis of Parkinson's disease, Essential Tremor, or Dystonia
• implanted Deep Brain Stimulator (DBS)
• have a 7T MRI
Exclusion Criteria:

• history of dementia
• women who are pregnant or breastfeeding
• other exclusion criteria (study staff will review)
Brain & Nervous System
DBS, Dystonia, Essential Tremor, ET, Movement Disorders, Parkinson's, Parkinson's Disease, PD
I'm interested
Share via email
See this study on ClinicalTrials.gov

The efficacy of incobotulinum toxin A injections for treatment of tinnitus: a randomized controlled trial

We are interested in the effects of injecting incobotulinum into muscles near the ear and neck to potentially reduce the symptoms of tinnitus. If successful, this procedure might reduce the burden many face by tinnitus. There are two stages of this study. The first stage, you may receive the study drug (incobtulinum) or a placebo. All participants will receive the study drug (incobtulinum) in the second stage.

Stephanie Standal
18 years and over
This study is NOT accepting healthy volunteers
STUDY00011665
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• unilateral or bilateral tinnitus present for at least 2 months
• score greater than 16 on the Tinnitus Handicap Inventory
Exclusion Criteria:

• known hypersensitivity to any botulinum toxin product
• received botulinum toxin for any medical reason in the past 4 months
• infection at proposed injection sites
• scheduled for neurological or otological surgery
• significant psychiatric history or associated diagnosis of major depression
• pregnant or breast feeding
Ear, Nose & Throat
Tinnitus
Visit study website
I'm interested
Share via email

RCT01437: Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with inflammatory bowel disease: The OPTIMIZE Trial

The purpose of this study is to find out if using a computer program (called iDose) to guide infliximab dosing is more effective and safer than using standard infliximab dosing over 52 weeks. All patients in this study will be receiving infliximab as part of their medical care, this study is only looking at two different methods of determining the dose and timing of administration.

Eugenia Shmidt
Not specified
This study is NOT accepting healthy volunteers
STUDY00013632
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 16 to 80 years of age
• diagnosis of moderate to severe Crohn's disease (CD) or Ulcerative colitis
• physician intends to prescribe infliximab for treatment
• have not previously taken infliximab
Exclusion Criteria:

• pregnant or breastfeeding
• complications of inflammatory bowel disease (IBD) such as abscess, need for ostomy (study staff review)
• current infection in last 6 months
• other significant medical conditions (heart, lungs, liver, endocrine etc.)
Digestive & Liver Health
Clinics and Surgery Center (CSC), Crohn's disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2022-52: Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) with Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Stem cell transplants (sometimes referred to as a bone marrow transplants) have been done for over 40 years but research continues to further refine the method to reduce side effects without affecting transplant success. The purpose of this study is to improve on transplant outcomes while reducing the potential side effects based on what has been learned from previous transplant studies using a reduced intensity preparative regimen. Information collected during this study (transplant outcomes and side effects) will be compared with the outcomes of the previous reduced intensity conditioning transplant study that enrolled more than 300 patients since 2002.

Mark Juckett
18 years and over
This study is NOT accepting healthy volunteers
STUDY00017906
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 75 years of age
• have a matched related donor
• additional criteria for diagnosis, and physical status (study staff will review)
Exclusion Criteria:

• women who are pregnant or breast feeding
• active central nervous system malignancy
• untreated active infection
• additional criteria for exclusion (study staff will review)
Cancer
Clinics and Surgery Center (CSC), Bone Marrow Transplant, Leukemia, Stem Cell Transplant
I'm interested
Share via email
See this study on ClinicalTrials.gov

Neural and Behavioral Markers of the Temporal Dynamics of Language Planning and Phonological Working Memory Processes in Persons Who Stutter

This is a study of persons who do and do not stutter between ages 7 and 65 years. This study is trying to figure out how attention skills influence memory, language, and speech fluency skills.

Jayanthi Sasisekaran
Not specified
This study is also accepting healthy volunteers
STUDY00013042
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 7 through 65 years
• remaining eligibility will be determined based on response to an intake survey
Children's Health, Community Health
adults, attention, fluency, language, memory, speech production, Stuttering, children
I'm interested
Share via email

A Phase 1/2, Multi-Center, Dose-Escalating Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to < 18 Years (and Young Adults Aged up to 21 Years) with FLT3-ITD Mutations (Protocol Number: AC220-A-U202/ADVL1822)

This is an open-label, multi-center, single arm, Phase 1/2 study to evaluate the safety, PK, PD, and efficacy of quizartinib administered in combination with fludarabine and cytarabine (FLA) (Re-Induction Cycles 1 and 2) chemotherapy for re-induction, with optional consolidation chemotherapy, and as a single agent continuation therapy (after optional, but strongly encouraged, HSCT per standard of care), in pediatric relapsed/refractory AML subjects aged ≥1 month old to <18 years old (and young adults up to 21 years old) with FLT3-ITD mutations.

Emily Greengard
1 month to 21 years old
STUDY00005937
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must meet all of the following criteria to be eligible for enrollment into the study: Has diagnosis of AML according to the World Health Organization (WHO) 2008 classification with ≥5% blasts in bone marrow, with or without extramedullary disease In first relapse or refractory to first-line high-dose chemotherapy with no more than 1 attempt (1 to 2 cycles of induction chemotherapy) at remission induction - prior HSCT is permitted Has presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood as defined in the protocol Is between 1 month and 21 years of age at the time the Informed Consent/Assent form is signed Has protocol-defined adequate performance status score Has fully recovered from the acute clinically significant toxicity effects of all prior chemotherapy, immunotherapy, or radiotherapy, per protocol guidelines Has protocol-defined adequate renal, hepatic and cardiac functions If of reproductive potential, is permanently sterile or agrees to use highly effective birth control upon enrollment, during the period of therapy, and for 6 months following the last dose of quizartinib, etoposide, fludarabine, methotrexate, or cytarabine, whichever is later If female of child-bearing potential, tests negative for pregnancy and agrees not to breast feed Male participants must be surgically sterile or willing to use highly effective birth control during the treatment period, and for 6 months following the last dose of quizartinib, etoposide, fludarabine, methotrexate, or cytarabine, whichever is later. Participant/legal representative is capable of understanding the investigational nature of the study, potential risks, and benefits, and the patient (and/or legal representative) signs a written assent/informed consent
Exclusion Criteria:
Participants who meet any of the following criteria will be disqualified from entering the study: Has been diagnosed with isolated central nervous system relapse, acute promyelocytic leukemia (APL), juvenile myelomonocytic leukemia, French-American-British classification M3 or WHO classification of APL with translocation, or with myeloid proliferations related to Down syndrome Has uncontrolled or pre-defined significant cardiovascular disease as detailed in the protocol Has systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment. The patient must be off vasopressors and have negative blood cultures for at least 48 hours prior to the start of systematic protocol therapy. Has known active clinically relevant liver disease (e.g., active hepatitis B or active hepatitis C) Has known history of human immunodeficiency virus (HIV) Has history of hypersensitivity to any of the study medications or their excipients Is receiving or is anticipated to receive concomitant chemotherapy, radiation, or immunotherapy other than as specified in the protocol Has any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise subject safety or compliance, interfere with consent/assent, study participation, follow up, or interpretation of study results Is currently participating in another investigative interventional procedure (observational or long-term interventional follow-up is allowed) Is otherwise considered inappropriate for the study by the Investigator
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors and Abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C). Protocol Number: I3Y-MC-JPCS

The study's purpose is to see if the drug abemaciclib is safe and effective in combination with temozolomide and irinotecan (Part A) and abemaciclib in combination with temozolomide (Part B) in pediatric and young adult participants with relapsed/refractory solid tumor and abemaciclib in Combination with Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients with Relapsed/Refractory Neuroblastoma (Part C).

Emily Greengard
Not specified
This study is NOT accepting healthy volunteers
STUDY00013998
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Parts A and B only: participants must be less than or equal to 18 years of age and with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies
• Part C only: participants must be less than (<) 21 years of age and with first relapse/refractory neuroblastoma and with any relapsed/refractory malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies Parts A, B & C:
• participants must have discontinued all previous treatments for cancer or investigational agents and must have recovered from the acute effects to Grade = < 1 at the time of enrollment
• able to swallow and/or have a gastric/nasogastric tube
Exclusion Criteria:

• received allogenic bone marrow or solid organ transplant
• diagnosed and/or treated additional malignancy within 3 years prior to enrollment that may affect the interpretation of results, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected in situ cervical and/or breast cancers
• pregnant or breastfeeding
Cancer
Refractory Solid Tumor, Relapsed Solid Tumor
I'm interested
Share via email
See this study on ClinicalTrials.gov

Understanding modifiable barriers to treatment adherence in youth with type 2 diabetes to inform intervention development

This study will seek to learn about barriers to management of Type 2 diabetes for children ages 10-17. This study is recruiting children, and their parent/guardian, who are managing with oral medication or insulin.

Amy Noser
Up to 18 years old
This study is NOT accepting healthy volunteers
STUDY00019484
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 10 to 17 years old
• confirmed diagnosis of type 2 diabetes
• prescribed pharmacologic therapy for treatment of type 2 diabetes (oral medication or insulin)
• live with a parent/caregiver at least 50% of the time who is willing to participate in the study
• able to read and speak English
• the parent/caregiver must be the adult who spends the largest proportion of time caring for the child (or at least 50%) & able to speak and read English
Exclusion Criteria:

• diagnosis of type 1 or monogenic diabetes
• evidence of significant cognitive deficits or a severe, persistent psychiatric disorder
Children's Health, Diabetes & Endocrine
Type 2 Diabetes
I'm interested
Share via email

Personalized immunomodulation in pediatric sepsis-induced MODS (PRECISE)

This is a large-scale multi-center study of personalized, targeted immune modulation in childre with sepsis-induced multiple organ dysfunction syndrome (MODS). This study is titled the “PeRsonalizEd immunomodulation in pediatriC sepsIS-inducEd MODS (PRECISE)”. The study includes two concurrent, immunophenotype-driven placebo controlled randomized controlled trils (RCTs) that will address the central hypothesis that individualized, pathophysiology-specific immunomodulation will improve outcomes from sepsis-induced MODS in children

Marie Steiner
SITE00001419
I'm interested
Share via email

MT2023-31: A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT) (HURCULES)

This research study is designed to compare a new gene therapy, known as OTL-203 (study drug), with a standard treatment called “allogeneic hematopoietic stem cell transplant” (allo-HSCT), to find out which is better for the treatment of MPS-IH.

Ashish Gupta
Up to 18 years old
This study is NOT accepting healthy volunteers
STUDY00020015
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 28 days old to no more than 30 months old
• confirmed laboratory diagnosis of MPS-IH
• evidence of altered GAG metabolism
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• previous allo-HSCT or gene therapy
• diagnosis of HIV, Hepatitis B, Hepatitis C, or Mycoplasma
• history of uncontrolled seizures
• contraindications for MRI scans
• study staff will review additional exclusion criteria
Rare Diseases
Hurler syndrome, MPS-IH, mucopolysaccharidosis type I
I'm interested
Share via email
See this study on ClinicalTrials.gov

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Psilocybin is the perception-altering drug found in ‘magic mushrooms’ and we want to learn more about visual perception in people taking psilocybin and how these relate to brain functions. Participants will be given an investigational study drug during 2 visits and asked to come in for a total of 7 study visits. Participants will also be required to refrain from using recreational drugs while enrolled in the study, including, but not limited to, hallucinogens, ketamine, and marijuana.

Jessica Nielson
18 years and over
This study is also accepting healthy volunteers
SITE00000856
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 25-65 years of age
• have at least a high school education (GED ok) and able to speak and write English
• experience taking psilocybin
• in good physical and mental health with BMI between 20.0 and 28.0 kg/M2
• have someone who can drive to study sessions at the University of MN
• live within 1 hour driving distance of the University of MN
• agree not to use any recreational drugs while in the study ( for example, hallucinogens, ketamine, and marijuana)
Exclusion Criteria:

• current or past history of a mental health issue
• currently taking any prescription medications on a daily basis, except birth control pills
• pregnant or breast feeding
• can't have a MRI
Mental Health & Addiction
psilocybin, visual perception
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2012-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

The primary purpose of this study is to record outcomes and patient characteristics in the Cancer Center’s and BMT databases for patients who are undergoing an allogeneic (donor) hematopoietic stem cell transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery (engraftment) and how patients are doing at 3 months and 6 months after the transplant. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.

Christen Ebens
Not specified
This study is NOT accepting healthy volunteers
1207M17321
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• up to 50 years old
• diagnosis of immunodeficiency or histiocytic disorder
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• pregnant or breastfeeding
• active, uncontrolled infection and/or HIV positive
• acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
Immune Diseases, Rare Diseases
Clinics and Surgery Center (CSC), Allogeneic Hematopoietic Stem Cell Transplant, Primary Immune Deficiencies
I'm interested
Share via email
See this study on ClinicalTrials.gov

teleABLE: Adapting a Behavioral Activation-Based Intervention to Reduce Post-Stroke Sedentary Behavior using Telehealth (Main Trial)

We are exploring ways to promote healthy lifestyles during stroke rehabilitation using a web-based rehabilitation program. The purpose of this study is to compare two intervention approaches: teleABLE and Healthy Lifestyles Education. Both interventions are delivered using video visits, so participants can complete all study activities from home

Emily Kringle
18 years and over
This study is NOT accepting healthy volunteers
STUDY00021288
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• diagnosed with stroke more than 6 months ago
• report 6 or more hours of sedentary behavior on a typical day
• live in a community-based setting (i.e., personal residence, assisted living facility)
• mobile within the home, with or without an assistive device and without physical assistance
Exclusion Criteria:

• Stroke and caregiver participants will be excluded if:
• currently receiving chemotherapy or radiation treatments for cancer
• have a medical diagnosis of neurodegenerative disorder (i.e., dementia, Parkinsons disease, multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma)
• received inpatient treatment for substance use disorder or psychiatric condition within the past 12 months
• have a history of skin sensitivity related to adhesives
• pregnant or expecting to become pregnant in the next 2 months
• live in an institutional setting
• currently incarcerated
• stroke participants will also be excluded if they have severe aphasia
Brain & Nervous System
caregiver, CVA, physical therapy, rehabilitation, remote, Stroke, virtual
I'm interested
Share via email

Prefrontal Cortical Stimulation in Severe Treatment Resistant Depression

This study looks at the use of an implanted brain stimulator for people who have treatment resistant depression. The change in brain function by EEG and symptoms of depression will be examined. This study is open to people 22-55 years old with Medicare or Medicare Advantage insurance.

Ziad Nahas
18 years and over
This study is NOT accepting healthy volunteers
STUDY00006945
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• ages 22-55
• diagnosis of chronic (greater than or equal to 2 years) depression
• poor response to three or more antidepressant medications (staff will review)
• had or refused ECT therapy
• under the regular care of a psychiatrist
• enrolled in a Medicare program
• have at least two people over 22 years of age and live within 30 minutes of participants residence who could respond to study staff if needed
• able to have a MRI scan
Exclusion Criteria:

• actively suicidal or have a history of an attempt within the last year
• have a history of another major mental health diagnosis
• have a positive drug test
• have an implanted brain device
• pregnant
• history of seizures
Mental Health & Addiction
Clinics and Surgery Center (CSC), Chronic Depression, Depression
I'm interested
Share via email
See this study on ClinicalTrials.gov

Hepatic Energy Fluxes, NASH, and Vertical Sleeve Gastrectomy

This study is looking at the liver function of people who have bariatric surgery. People who want to be in this trial must be obese, have abnormal liver function tests & prediabetes or type 2 diabetes. The study includes assistance with diet and exercise for a year after surgery.

Sayeed Ikramuddin
18 years and over
This study is NOT accepting healthy volunteers
STUDY00006269
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18 to 67 years
• diagnosis of non-alcoholic steatohepatitis (NASH)
• Body Mass Index (BMI) 30.0-55.0 kg/m2
• willing to have surgical treatment and have insurance with no exclusion for obesity related treatments or management of obesity surgery complications
• live or work within approximately three-hour traveling time from the study clinic for the duration of the one-year trial
Exclusion Criteria:

• cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months
• pulmonary embolus or thrombophlebitis in the past six months
• cancer diagnosis unless disease free for five years
• alcohol intake more than one drink per day
• other physical or mental health disease (study staff will review)
Digestive & Liver Health
Clinics and Surgery Center (CSC), Bariatric surgery, NASH, fatty liver, gastrectomy, gastric sleeve, sleeve, sleeve, VSG, weight loss
I'm interested
Share via email
See this study on ClinicalTrials.gov

Minnesota KPMP CKD and Resilient Diabetes Recruiting Site (KPMP)

The Kidney Precision Medicine Project (KPMP) is a research study. Our goal is learn more about kidney injury and kidney disease. By studying your kidneys, we may learn more about why chronic kidney disease happens and how to treat it more effectively or even how to prevent it. Or participants have had diabetes for many years and have not clinical signs of chronic kidney disease. By studying your kidneys, we may learn more about the factors that help protect you from kidney disease. KPMP will last for at least 10 years.

Patrick Nachman
18 years and over
This study is NOT accepting healthy volunteers
SITE00001290
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• diagnosis acute or chronic kidney (renal) disease with diabetes mellitus (type 1 or 2) OR associated with hypertension
• persistent kidney damage based on specific lab values at least 3 months apart (study staff will review)
Exclusion Criteria:

• Body Mass Index (BMI) greater than 40 kg/m2
• any allergic reaction to iodinated contrast
• receiving chemotherapy or radiation to treat cancer
• transplant recipient (includes solid transplant and bone marrow)
• unwilling to receive blood transfusion (if needed)
• women who are pregnant
Kidney, Prostate & Urinary
Clinics and Surgery Center (CSC), Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Chronic Kidney Disease
I'm interested
Share via email
See this study on ClinicalTrials.gov

Safety and Acceptability of Patient -administered Sedation During Mechanical Ventilation

This study is comparing the benefits and adverse effects of two delivery methods to help patients relax and decrease anxiety during his/her time on mechanical ventilation. This study is not examining the medication but rather the process of how the patient receives the sedation medication: patient controlled or usual care.

Craig Weinert
18 years and over
This study is NOT accepting healthy volunteers
1605M88241
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• receiving mechanical ventilation (ventilator) in the Intensive Care Unit
• receiving medication for sedation or pain
Exclusion Criteria:

• prone (facing down) ventilation being used
• low blood pressure that is being treated with medication
• unstable medical condition (staff will review)
Brain & Nervous System, Respiratory System
ICU, Intensive Care Unit, Pain, Ventilator
I'm interested
Share via email
See this study on ClinicalTrials.gov

Accelerating Therapies for Refractory SJIA Patients

This research study aims to learn more about the causes of Systemic Juvenile Idiopathic Arthritis (sJIA) including its complications such as Macrophage Activation Syndrome (MAS) and sJIA associated lung disease and identify new therapeutic targets. The study is asking for biological samples from those diagnosed with sJIA as well as their family members.

Mona Riskalla
Up to 18 years old
This study is NOT accepting healthy volunteers
SITE00001576
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 6 months old
• new onset SJIA or established SJIA with or without lung and/or liver complications
• parent or sibling of the enrolled child will also be asked to participate
Exclusion Criteria:

• illness sufficient to prohibit study participation
• inability to cooperate with the study
Arthritis & Rheumatic Diseases, Rare Diseases
SJIA, Systemic Juvenile Idiopathic Arthritis
I'm interested
Share via email

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The study entails 2 visits over a 3-month period. On enrollment, participants will be scheduled for the 2 visits, during which fasting blood samples will be collected.

Reena Kartha
18 years and over
This study is also accepting healthy volunteers
STUDY00013672
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• ages 18 to 80
• healthy volunteers without any known diagnosis
Exclusion Criteria:

• hematological cancer or other uncontrolled medical conditions
Rare Diseases
Gaucher Disease, Healthy Volunteers
I'm interested
Share via email

Neural mechanisms of early visual dysfunction in psychosis

The purpose of this study is to look at symptoms, thoughts, and behaviors related to the way a person sees the world. This is called visual perception. This study will also look at brain function. We will study these things in people with and without psychosis. People with psychosis see the world differently than others. For example, they may experience hallucinations. We are interested in understanding how differences in the way people see the world relate to brain circuits. This project will use visual and behavioral experiments, EEG, and Magnetic Resonance Imaging (MRI) to look at how visual perception is different in people with and without psychosis. This research study has three visits lasting 2-4 hours each. We expect that these visits will take place over 2-3 months, depending on your availability and preferences.

Michael-Paul Schallmo
18 years and over
This study is also accepting healthy volunteers
STUDY00007958
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18-60 years old
• normal or corrected-to-normal vision
• current diagnosis of schizophrenia or schizoaffective disorder
Exclusion Criteria:

• claustrophobia
• current substance dependence (other than nicotine)
• any vision problem (e.g. strabismus/crossed eyes, lazy eye, color blindness)
• current or past diagnosis of bipolar I disorder
Brain & Nervous System, Vision & Eyes
EEG, MRI, neuroscience, psychosis, vision
I'm interested
Share via email

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy? System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

The purpose of this study is to determine whether active Vagal Nerve Stimulation (VNS) Therapy is better than no stimulation VNS Therapy in improving health outcomes for subjects with Treatment-Resistant Depression (TRD). All participants in this study will receive a VNS Therapy surgical implant, which works to reduce the symptoms of depression by sending mild electrical pulses to the vagus nerve in the neck. The vagus nerve is connected to areas of the brain associated with controlling the mood. Data will be collected on responses to study treatments, quality of life, productivity, and use of healthcare services.

Ziad Nahas
18 years and over
This study is NOT accepting healthy volunteers
SITE00000818
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• current diagnosis of major depression for at least two years or at least 4 episodes of major depression
• have an inadequate improvement in symptoms with at least 4 antidepressant treatments
• on at least one antidepressant with a stable drug schedule for at least 4 weeks
• enrolled in Medicare or Medicare Advantage
Exclusion Criteria:

• Currently uses, or is expected to use during the study, short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy
• acute suicide risk or suicide attempt within 6 months
• history of other major mental health diagnosis (staff will review)
• treatment with another device or experimental drug
Mental Health & Addiction
Depression, Major depression

Cortical Inhibitory Biomarkers of Acute Suicidal States in Adolescents

Prospective study investigating brain activity associated with markers of suicidal behavior (SB) in adolescents.

Charles Lewis
Up to 18 years old
This study is also accepting healthy volunteers
STUDY00011433
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• ages 13-21
• current diagnosis of depression
• prior history of either thoughts about suicide, or suicidal behaviors (a suicide attempt or a planned attempt that was stopped before it began)
• must be able to communicate verbally and in writing in English
• parental permission is needed for participants aged 17 or younger
• must have reliable internet connection
Healthy volunteers
also needed
Exclusion Criteria:

• Active substance use in the past month
• Neurological disorders such as seizures, head injury
Children's Health, Mental Health & Addiction
Depression, Suicide, Adolescent
I'm interested
Share via email

Food Parenting Practices on Child Dietary Intake

This research is being done to help better understand the ways parents interact with their children at meal and snack times at different time points during the day and in different circumstances. We want to study how the feeding approaches affect the child’s dietary intake over time. Study participation will be two years with activities every six months.

Katie Loth
Up to 18 years old
This study is also accepting healthy volunteers
00018340
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Family attends Fairview Primary Care clinic
• Child between 3-5 years of age
• Caregiver has primary responsibility of feeding child outside of childcare
• Child must live at least 50% of the time or more with the primary guardian
• Caregiver must be able to speak and read English or Spanish
Exclusion Criteria:

• Caregiver is less than 18 years of age
• Child is in the foster system
Children's Health, Community Health
child, children, eat, eating, feeding, food, kid, nutrition, parent, preschool, psychology
I'm interested
Share via email

Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to < 12 years: 56-week, double-blind, randomised, placebo-controlled trial

This study will compare the effect of liraglutide 3.0 mg subcutaneous once daily versus liraglutide placebo on weight management in children aged 6 to <12 years with placebo. The study will also compare the effect of liraglutide 3.0 mg s.c. once daily versus placebo in children aged t to 12 years with obesity on cardiovascular risk factors and metabolism.

Claudia Fox
Up to 18 years old
This study is also accepting healthy volunteers
SITE00001083
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 10 to 17 years old
• BMI greater than the 95th percentile for age and sex
• willing to make life style modifications that are part of the study (study staff will review)
Exclusion Criteria:

• history of heart problems (stroke, congenital heart disease, heart arrhythmia etc.)
• type 1 or type 2 diabetes
• use of any weight loss medication in the past 6 months
• history of bariatric surgery
• taking ADHD stimulants
• history of mental illness (suicide attempt, mania, psychosis, substance abuse)
• pregnant or breast feeding
Children's Health
Obesity, Weight, Weight management
I'm interested
Share via email
See this study on ClinicalTrials.gov

Quantifying the Individual Heterogeneity of Presentation and Symptoms of Cognitive Impairment in Long COVID

This questionnaire and cognitive task study is being done to learn how different activities, like exercise, sleep, and stress, may affect symptoms of long COVID. We also want to know how symptoms may fluctuate over different times during the day and over several weeks. The study will take about 4 weeks to complete and will be done remotely.

Kelvin Lim
18 years and over
This study is NOT accepting healthy volunteers
STUDY00017662
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• able to speak English
• have access to a compute with internet access
• history of having COVID-19
• continue to experience symptoms of long COVID-19 such as fatigue, "brain fog", trouble sleeping, headaches, etc.
Exclusion Criteria:

• never tested positive for COVID-19
Brain & Nervous System, COVID-19
brain fog, COVID-19, fatigue, Long COVID-19
Visit study website
I'm interested
Share via email

COG AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Peter Gordon
Not specified
This study is NOT accepting healthy volunteers
SITE00000723
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• patients must be > 365 days and < 25 years of age
• participant has newly diagnosed B-ALL or MPAL with ?25% blasts on a bone marrow (BM) aspirate or newly diagnosed B-LLy
• see link to clinicaltrials.gov for complete inclusion criteria
Exclusion Criteria:

• patients with Down syndrome are not eligible
• patients with acute undifferentiated leukemia (AUL) are not eligible
• female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
• lactating women who plan to breastfeed their infants while on study and for 2 months after the last dose of inotuzumab ozogamicin.
• see link to clinicaltrials.gov for complete exclusion criteria
Cancer
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Leukemia, Testicular Leukemia
I'm interested
Share via email
See this study on ClinicalTrials.gov

R01HL153613: Comprehensive Proteomic Classifier for the Molecular Characterization of Pulmonary Sarcoidosis

This study proposes to collect lung fluid to identify potential biomarkers associated with pulmonary sarcoidosis.

Maneesh Bhargava
18 years and over
This study is NOT accepting healthy volunteers
SITE00001283
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• age 18-80
• contact umnsarc@umn.edu for inclusion/exclusion criteria
Exclusion Criteria:

• history/current use of cigarette, e-cigarette, vaping or marijuana smoking
• history/current use of nicotine products
• presence of underlying chronic condition
• inability to undergo procedure using IV sedation
• weight < 110 lbs. & BMI > 35 kg/m2
• pregnant and/or breast feeding
• history/current use of chronic immunosuppressive medications
• contact umnsarc@umn.edu for inclusion/exclusion criteria
Breathing, Lung & Sleep Health, Respiratory System
Sarcoid, Lung, Pulmonary, Sarcoidosis, Clinics and Surgery Center (CSC)
I'm interested
Share via email

Vasomotor symptoms of menopause and cardiovascular disease: What is the link?

Study to examine the physiological responses that occur during a hot flush in postmenopausal women

Manda Keller-Ross
18 years and over
This study is also accepting healthy volunteers
STUDY00013742
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participants must have completed menopause and experience either no menopausal hot flashes or experience three menopausal hot flashes a day.
Exclusion Criteria:

• Reported nicotine/tobacco use within the last six months
• Diabetic or asthmatic
• Diagnosed significant carotid stenosis
• History of significant autonomic dysfunction, heart disease, respiratory disease, or severe neurologic condition such as stroke or traumatic brain injury
• Existing metabolic or endocrine abnormalities
• Use of heart/blood pressure medications that are determined to interfere with study outcomes
• Use of oral contraceptives (or other hormonal contraceptives, including intrauterine devices or contraceptive implants) and/or hormone therapy
• Pregnant or breastfeeding
• Unwilling or unable to refrain from consuming caffeine or alcohol in the 12 hours before visit two and three.
• Unwilling or unable to refrain from vigorous exercise (at least 10 minutes in duration) in the 12 hours before visit two or three
• Unwilling or unable to fast in the eight hours before visit two or three
• Body mass index ? 35 kg/m2
Blood Disorders, Brain & Nervous System, Women's Health
autonomic nervous system, Blood pressure, hot flashes, hypertension, menopause, night sweats
I'm interested
Share via email
See this study on ClinicalTrials.gov

MT2020-27: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This purpose of this study is to identify a safe dose level for the study drug, E7777, when given with standard tisagenlecleucel therapy (also known by its brand name, Kymriah, is an immunotherapy that is made from the participants own blood cells) in participants with Diffuse Large B-Cell Lymphoma (DLBCL). Up to three dose levels of E7777 will be tested.

Veronika Bachanova, MD
18 years and over
This study is NOT accepting healthy volunteers
STUDY00011895
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of a relapse or refractory large B cell lymphoma, for which treatment with Kymriah is planned
• received two or more lines of systemic therapy
• able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• participants of child bearing age must use birth control for 30 days following completion of treatment
• additional inclusion criteria (study staff will review)
Exclusion Criteria:

• women who are pregnant or breast feeding
• CNS involvement by malignancy
• eye disease or complaints visual acuity impairment, color or shape distortion, or blurred vision - potential participants are required to have an eye exam as part of screening
• additional exclusion criteria (study staff will review)
Cancer
Clinics and Surgery Center (CSC), Diffuse Large B Cell Lymphoma, DLBCL, High-grade B-cell Lymphoma
I'm interested
Share via email
See this study on ClinicalTrials.gov